S Jones, C Vogel, A Arkhipov, L Fehrenbacher, P Eisenberg, B Cooper, S Honig, A Polli, F Whaley, E di Salle, J Tiffany, A Consonni, L Miller
PURPOSE: To assess the antitumor activity, safety, and hormone-suppressive effects of the irreversible aromatase inactivator, exemestane (Aromasin, Pharmacia & Upjohn, Kalamazoo, MI), administered as third-line hormone therapy to postmenopausal women with metastatic breast cancer that is refractory to tamoxifen and megestrol acetate. PATIENTS AND METHODS: Exemestane was administered at a dose of 25 mg/d orally until patients experienced disease progression. The efficacy and safety of exemestane were clinically and radiographically evaluated...
November 1999: Journal of Clinical Oncology